X2S1 Stock Chart & Stats
€9.60
€0.15(1.56%)
At close: 4:00 PM EDT
€9.60
€0.15(1.56%)
Day’s Range― - ―
52-Week Range€8.70 - €11.80
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€5.77B
Enterprise Value€20.52K
Total Cash (Recent Filing)€61.60B
Total Debt (Recent Filing)€108.65B
Price to Earnings (P/E)6.3
Beta0.37
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)11.35
Shares Outstanding268,362,150
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-4.41
Price to Book (P/B)0.64
Price to Sales (P/S)0.10
P/FCF Ratio4.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Distribution & Retail NetworkSinopharm operates both B2B distribution and retail pharmacy channels across pharmaceuticals, devices and logistics. This diversified model reduces single-channel dependency, supports stable revenue mix and long-term resilience to shifts in tendering or retail demand over a multi-month horizon.
Consistent Positive Free Cash FlowFCF covering a large share of net income shows earnings translate into cash, enabling capex, working-capital funding, dividends or debt servicing without immediate reliance on new financing. That cash conversion supports operational flexibility amid weaker top-line trends.
Established Institutional ReachThe company's nationwide access to hospitals, clinics and pharmacies and large operating scale underpin durable commercial relationships and distribution advantages. Scale helps negotiate procurement, manage inventory and deliver logistics services that competitors find harder to replicate.
Bears Say
Recent Revenue DeclineA multi-year slowdown culminating in a ~2.8% revenue drop in 2025 signals waning end-market demand or pricing pressure. Sustained top-line erosion reduces operating leverage, constrains reinvestment capacity and raises risk that margins and returns may remain depressed over the next several quarters.
Margin CompressionFalling gross and EBITDA margins reflect tighter spreads or higher cost-to-serve in distribution and retail. Persistent margin pressure erodes profitability even if revenue stabilizes, reducing free cash flow and ROE and limiting ability to fund growth or maintain shareholder distributions over the medium term.
Rising LeverageA meaningful one-year rise in debt-to-equity increases financial risk and reduces balance-sheet flexibility. Higher leverage raises interest and refinancing vulnerability, constraining the firm's ability to invest or respond to market shocks without compressing cash buffers or altering dividend and capex plans.
Sinopharm Group Co News
X2S1 FAQ
What was Sinopharm Group Co’s price range in the past 12 months?
Sinopharm Group Co lowest stock price was €8.70 and its highest was €11.80 in the past 12 months.
What is Sinopharm Group Co’s market cap?
Sinopharm Group Co’s market cap is €5.77B.
When is Sinopharm Group Co’s upcoming earnings report date?
Sinopharm Group Co’s upcoming earnings report date is Aug 21, 2026 which is in 6 days.
How were Sinopharm Group Co’s earnings last quarter?
Currently, no data Available
Is Sinopharm Group Co overvalued?
According to Wall Street analysts Sinopharm Group Co’s price is currently Overvalued.
Does Sinopharm Group Co pay dividends?
Sinopharm Group Co does not currently pay dividends.
What is Sinopharm Group Co’s EPS estimate?
Sinopharm Group Co’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sinopharm Group Co have?
Sinopharm Group Co has 268,362,150 shares outstanding.
What happened to Sinopharm Group Co’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Sinopharm Group Co?
Currently, no hedge funds are holding shares in DE:X2S1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sinopharm Group Co Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
2.83%
12-Months-Change
Fundamentals
Return on Equity
4.82%
Trailing 12-Months
Asset Growth
3.79%
Trailing 12-Months
Company Description
Sinopharm Group Co
Sinopharm Group Co. Ltd. is a prominent Chinese enterprise specializing in the wholesale and retail of pharmaceuticals, medical devices, and other healthcare products. The company's diverse operations are structured into four key segments. The Pharmaceutical Distribution segment is responsible for supplying a wide array of pharmaceutical products to various healthcare entities, including hospitals, clinics, and retail pharmacies. This segment also provides comprehensive logistics and value-added services to both domestic and international manufacturers and suppliers of pharmaceutical and healthcare items. The Medical Devices segment focuses specifically on the distribution of medical equipment. Through its Retail Pharmacy segment, the company operates and franchises an extensive chain of drugstores, which totaled 10,259 locations as of December 31, 2021. The Other Business segment encompasses the manufacturing and sale of pharmaceutical products, chemical reagents, and laboratory supplies. Beyond these core activities, Sinopharm Group also engages in property rental and management, distributes specialized products such as Chinese herbal medicines, antibiotics, and biological products, and offers a suite of services. These include IT development, medicine, business, health, and market information consulting, international trade (import/export of goods and technology), market investigation, and convention and exhibition services. Furthermore, the company is involved in medical project investment, consulting, and technology training. To enhance its commercial capabilities and transformation, Sinopharm Group Co. Ltd. maintains a strategic partnership with I-Mab. Founded in 2003, the company is headquartered in Shanghai, China, and operates as a subsidiary of Sinopharm Industrial Investment Co., Ltd.